- Home
- NUVL vs CCCS Comparison
NUVL vs CCCS Comparison
Compare NUVL & CCCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- CCCS
- Stock Information
- Founded
- NUVL 2017
- CCCS 1980
- Country
- NUVL United States
- CCCS United States
- Employees
- NUVL 200
- CCCS N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- CCCS Computer Software: Prepackaged Software
- Sector
- NUVL Health Care
- CCCS Technology
- Exchange
- NUVL Nasdaq
- CCCS Nasdaq
- Market Cap
- NUVL 6.0B
- CCCS 5.8B
- IPO Year
- NUVL 2021
- CCCS N/A
- Fundamental
- Price
- NUVL $83.09
- CCCS $9.27
- Analyst Decision
- NUVL Strong Buy
- CCCS Buy
- Analyst Count
- NUVL 9
- CCCS 7
- Target Price
- NUVL $118.89
- CCCS $11.43
- AVG Volume (30 Days)
- NUVL 396.7K
- CCCS 5.3M
- Earning Date
- NUVL 11-11-2025
- CCCS 10-27-2025
- Dividend Yield
- NUVL N/A
- CCCS N/A
- EPS Growth
- NUVL N/A
- CCCS N/A
- EPS
- NUVL N/A
- CCCS 0.00
- Revenue
- NUVL N/A
- CCCS $996,961,000.00
- Revenue This Year
- NUVL N/A
- CCCS $13.57
- Revenue Next Year
- NUVL N/A
- CCCS $9.04
- P/E Ratio
- NUVL N/A
- CCCS $30,933.33
- Revenue Growth
- NUVL N/A
- CCCS 9.60
- 52 Week Low
- NUVL $55.54
- CCCS $8.14
- 52 Week High
- NUVL $106.32
- CCCS $12.88
- Technical
- Relative Strength Index (RSI)
- NUVL 56.32
- CCCS 44.18
- Support Level
- NUVL $81.02
- CCCS $8.96
- Resistance Level
- NUVL $86.34
- CCCS $9.55
- Average True Range (ATR)
- NUVL 3.63
- CCCS 0.22
- MACD
- NUVL 0.28
- CCCS -0.00
- Stochastic Oscillator
- NUVL 66.33
- CCCS 35.06
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About CCCS CCC Intelligent Solutions Holdings Inc.
CCC Intelligent Solutions Holdings Inc is a provider of cloud, mobile, AI, telematics, hyperscale technologies and applications for the property and casualty insurance economy. The company's SaaS platform connects trading partners, facilitates commerce, and supports mission-critical, and AI-enabled digital workflows. It operates in a single segment being Domestic segment which provides SAAS platform for the P&C insurance economy and derives revenues from providing customers with software subscriptions to the platform in addition to providing professional services and non-software services. The company has its presence in United States and China. Majority of the revenue is generated from United States.